In the CASTING open-label single-arm prospective trial, the proportion of patients with no evidence of disease activity (NEDA) at Year 2 was high: 74.8%–80.4% of patients were free from clinical disease activity, while 91.5% of patients were free from MRI disease activity . NEDA was maintained from Year 1 over Year 2. No new safety signals were observed.
The CASTING results were presented as a late-breaking abstract by Prof. Patrick Vermersch (CHU Lille, France). CASTING is a phase 3b study evaluating the efficacy and safety of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) patients with suboptimal response to 1 or 2 prior disease-modifying treatments (DMTs). Prof. Vermersch reported the study's primary efficacy endpoint, 2-year NEDA rates, including:
- no protocol-defined relapses;
- no 24-week confirmed disability progression;
- no T1-weighted gadolinium-enhancing lesions after Week 8 re-baselining;
- no new/enlar...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Long-term cardiovascular safety of erenumab in migraine patients Next Article
Extubation after thrombectomy: the sooner, the better »
Table of Contents: EAN 2020
Headache and Pain
Neuromyelitis Optica Spectrum Disorder
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.